Individualized Genomic Testing Allows for Tailored Cancer Treatment, New Drug Research Newswise PHILADELPHIA Just like a massive iceberg jutting out of the ocean, many of cancers genetic underpinnings remain hidden under the surface, impossible to predict or map from above. The foreboding shadows and shapes that appear on CT scans and MRIs and even in the field that doctors see when they zoom in to look at cancer cells under a high-powered microscope are just the tip of the iceberg. Penn Medicines new Center for Personalized Diagnostics, a joint initiative of the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and the Abramson Cancer Center, is diving deeper into each patients tumor with next generation DNA sequencing. Continue reading
Tag Archives: pathology
Getting medical ideas to market: U-M Medical School and U-M Tech Transfer launch $7.5M fund for innovators
$2.4M grant from Michigan Economic Development Corp. jumpstarts Michigan Translational Research & Commercialization for Life Sciences effort ANN ARBOR, Mich., March 4, 2013 /PRNewswire-USNewswire/ –A new $7.5 million fund will help University of Michigan medical discoveries make the leap from the laboratory to the market, accelerating their potential to help patients. Funded in part by a new $2.4 million grant from the Michigan Economic Development Corporation’s 21st Century Jobs Fund, the new effort will help the U-M Medical School and U-M Tech Transfer identify, nurture and “fast forward” medical research projects with a high potential of commercial success. Continue reading
New Penn Medicine Blood Center to Unify Patient Care, Research, and Public Education Efforts for Blood Disorders
Newswise PHILADELPHIA Penn Medicine will establish the Philadelphia regions first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses. The Penn-CHOP Blood Center for Patient Care and Discovery will bring together a multi-disciplinary team of experts to provide cutting edge patient care and research for diseases including sickle cell disease, thalassemia, bone marrow failure, and bleeding and clotting disorders. The effort will include Perelman School of Medicine hematology faculty from both Penn Medicine and the Childrens Hospital of Philadelphia, who will work closely with pathology, laboratory, and transfusion medicine physicians and scientists, pharmacologists, investigators in Penns Abramson Cancer Center, the Institute for Translational Medicine and Therapeutics and the Penn Cardiovascular Institute, among others Continue reading
Dr. Keith Knutson Joins the Vaccine & Gene Therapy Institute of Florida as A Research Program Director in Oncology
PORT ST. LUCIE, Fla.–(BUSINESS WIRE)– The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Keith Knutson, Ph.D., Program Director. Dr. Continue reading
UMMS targets new therapy for Alzheimer’s – Video
UMMS targets new therapy for Alzheimer's An international team of researchers from UMass Medical School, the University of Bonn and the Center for Advanced European Studies and Research in Germany have shown that an immune and inflammatory process already established as a clinical target for rheumatoid arthritis plays an important role in the pathology of Alzheimer's disease, meaning drugs now used to target that process may benefit patients with Alzheimer's. This process results in the mature production of the pro-inflammatory cytokine called interleukin-1 beta (IL-1 beta;) and is involved in the body's defense against infection. The finding, published in Nature, points to the possibility that drugs that disrupt the production of IL-1 beta;, such as those for rheumatoid arthritis, may also prove beneficial for patients with Alzheimer's. Continue reading
Meditech Pathology Laboratory Pune – Video
Meditech Pathology Laboratory Pune Meditech Pathology Laboratory was established in 1999 with the aim of providing a host of superlative diagnostic services under one roof. Dr Prashant Patil, a pathologist Harun Maner technologist with Miss. Anita Nagare technologist founded the lab starting out with a basic setup. Continue reading
Penn Medicine's Carl June, MD, Named Co-Recipient of 2012 Ernest Beutler Lecture and Prize from American Society of …
ATLANTA — Carl H. Continue reading
Human Gene Therapy articles describe two novel anti-tumor therapies
Published on October 26, 2012 at 4:12 AM Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Human Gene Therapy website at http://www.liebertpub.com/hum. Continue reading
Athersys Presents Research Progress in Its Multiple Sclerosis Program
CLEVELAND, Oct. Continue reading
RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer
ANN ARBOR, Mich.–(BUSINESS WIRE)– RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration welcomes Steven Bramer, PhD to its senior management team as Chief Development Officer. Dr Continue reading
New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia
Public release date: 25-Jul-2012 [ | E-mail | Share ] Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News New Rochelle, NY, July 25, 2012A novel approach to gene therapy that instructs a person’s own cells to produce more of a natural disease-fighting protein could offer a solution to treating many genetic disorders. The method was used to achieve a 2- to 3-fold increase in production of a protein deficient in patients with Friedreich’s ataxia, as described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc Continue reading
Douglas Wallace to Receive Gruber Foundation 2012 Genetics Prize
PHILADELPHIA Douglas C. Wallace, PhD, professor of Pathology and Laboratory Medicine, at the Perelman School of Medicine, University of Pennsylvania, is the recipient of the 2012 Genetics Prize of the Gruber Foundation. Continue reading
Dr. Douglas Wallace to Receive Gruber Foundation 2012 Genetics Prize
Newswise Douglas C. Wallace, Ph.D., director of the Center for Mitochondrial and Epigenomic Medicine at The Childrens Hospital of Philadelphia, will receive the 2012 Genetics Prize of The Gruber Foundation. This prestigious international awarda $500,000 prizerecognizes Wallaces pioneering scientific investigations of the wide-ranging role of mitochondria in the development of disease and as markers of human evolution. Continue reading
Cryopraxis, Sponsor of Stem Cell Research is Represented at Bio2012 in Boston
RIO DE JANEIRO–(BUSINESS WIRE)– Cryopraxis established in 2001 as the pioneer private umbilical cord blood bank in Brazil will be present at Bio 2012 in Boston. Eduardo Cruz, chairman of the board, will be a speaker at the Brazilian break-out session speaking about The Brazilian Biotechnology Sector and showing the results of the company’s commitment to R&D. Cryopraxis has already collected and processed more than 25000 cord blood units (CBU) and is actively involved in several R&D projects in Brazil and abroad Continue reading
Single-dose vaccine for treatment of cocaine addiction
Published on June 19, 2012 at 3:59 AM A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the Human Gene Therapy website (http://www.liebertpub.com/hum) Continue reading
Researchers at Boston Children's Hospital identify a genetic cause for CLOVES syndrome
Public release date: 31-May-2012 [ | E-mail | Share ] Contact: Erin Tornatore erin.tornatore@childrens.harvard.edu 617-919-3110 Children’s Hospital Boston Boston, Mass. Using advanced technologies for rapidly sequencing and analyzing DNA from clinical and pathologic samples, a multidisciplinary research team consisting of geneticists, pathologists and surgeons at Boston Children’s Hospital has identified the genetic basis for CLOVES syndrome, a rare congenital malformation and overgrowth disorder. The discovery raises the hope that, for the first time, it will be possible to develop targeted medical treatments capable of delaying, reversing or possibly preventing CLOVES’s debilitating consequences. Continue reading
Forensic medicine increasingly popular career option
by Jenne Lajiun. Posted on May 12, 2012, Saturday KOTA KINABALU: Forensic pathology or forensic medicine is becoming a popular career option for many doctors. Continue reading
Penn Medicine-Led Cardiovascular Health Screening Technology Receives Innovative Development Funding from American …
PHILADELPHIA The American Heart Association (AHA) announced today that they have made their first investment through the Science & Technology Accelerator Program into CytoVas, LLC. The company was founded by Jonni S. Continue reading
Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Public release date: 7-May-2012 [ | E-mail | Share ] Contact: David Sampson ajpmedia@elsevier.com 215-239-3171 Elsevier Health Sciences Philadelphia, PA, May 7, 2012 While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the blood of patients with prostate cancer, can predict whether a patient will experience a relapse, and the nature of the relapse aggressive or indolent. Continue reading
Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome – Part 1 Clinical – Video
11-04-2012 16:34 Demystifying Medicine Seminar Series Date: Monday, February 27, 2012 Location: McMaster University Medical Centre, Hamitlon, Ontario, Canada Speakers: Dr. Peter Margetts, Associate Professor, Departments of Medicine and Pathology and Molecular Medicine Director, MD/PhD Program, McMaster University Dr. Continue reading